Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 17/20 | 0.72 |
| ▸ | TACR1 | P25103 | 17/20 | 0.72 |
| ▸ | TACR3 | P29371 | 9/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.70 |
| ▸ | CCR5 | P51681 | 2/20 | 0.60 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6543268 | 0.99 | TACR2 (0.71) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL6450782 | 0.91 | TACR2 (0.71) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL6544537 | 0.89 | TACR2 (0.69) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL7310856 | 0.85 | TACR2 (0.73) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL8015907 | 0.85 | TACR2 (0.72) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL7834929 | 0.84 | TACR2 (1.00) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL6448486 | 0.83 | TACR1 (0.79) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL7090412 | 0.83 | TACR1 (0.79) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL6449952 | 0.83 | TACR1 (0.79) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL24855513 | 0.83 | TACR2 (0.79) | TACR2TACR1TACR3CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1517708-A1 | COMBINATION TREATMENT FOR DEPRESSION AND ANXIETY BY NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2005-03-30 | — | — | EP | claimed |
| US-20040220223-A1 | Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2004-11-04 | — | — | US | claimed |
| US-20040006135-A1 | Combination treatment for depression and anxiety | PFIZER INC. | 2004-01-08 | — | — | US | claimed |
| WO-2004000355-A1 | COMBINATION TREATMENT FOR DEPRESSION AND ANXIETY BY NK1 AND NK3 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2003-12-31 | — | — | WO | claimed |
| EP-1241168-A1 | Human NK3 receptor-selective antagonist compounds, process for their obtention and pharmaceutical compositons containing them | SANOFI-SYNTHELABO (FR) | 2002-09-18 | — | — | EP | claimed |
| US-20020049329-A1 | Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2002-04-25 | — | — | US | claimed |
| EP-1192952-A2 | Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist | Pfizer Products Inc. (US) | 2002-04-03 | — | — | EP | claimed |
| US-6028082-A | FOR TRATING PSYCHOLOGICAL DISORDERS | SANOFI-SYNTHELABO (FR) | 2000-02-22 | — | — | US | claimed |
| EP-1517708-A1 | COMBINATION TREATMENT FOR DEPRESSION AND ANXIETY BY NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2005-03-30 | — | — | EP | disclosed |
| US-20040220223-A1 | Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2004-11-04 | — | — | US | disclosed |
| US-6710042-B2 | PIPERIDINE DERIVATIVES; TREATMENT OF PSYCHOLOGICAL DISORDERS | SANOFI-SYNTHELABO (FR) | 2004-03-23 | — | — | US | disclosed |
| US-20040006135-A1 | Combination treatment for depression and anxiety | PFIZER INC. | 2004-01-08 | — | — | US | disclosed |
| WO-2004000355-A1 | COMBINATION TREATMENT FOR DEPRESSION AND ANXIETY BY NK1 AND NK3 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2003-12-31 | — | — | WO | disclosed |
| EP-1241168-A1 | Human NK3 receptor-selective antagonist compounds, process for their obtention and pharmaceutical compositons containing them | SANOFI-SYNTHELABO (FR) | 2002-09-18 | — | — | EP | disclosed |
| US-20020049329-A1 | Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2002-04-25 | — | — | US | disclosed |
| EP-1192952-A2 | Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist | Pfizer Products Inc. (US) | 2002-04-03 | — | — | EP | disclosed |
| US-6291672-B1 | FOR THE PREPARATION OF DRUGS USEFUL IN THERAPY OF PSYCHIATRIC DISEASES, DISEASES OF PSYCHOSOMATIC ORIGIN, HYPERTENSION | SANOFI-SYNTHELABO (FR) | 2001-09-18 | — | — | US | disclosed |
| EP-1019373-A1 | NOVEL HUMAN NK 3? RECEPTOR-SELECTIVE ANTAGONIST COMPOUNDS, METHOD FOR OBTAINING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI-SYNTHELABO (FR) | 2000-07-19 | — | — | EP | disclosed |
| US-6028082-A | FOR TRATING PSYCHOLOGICAL DISORDERS | SANOFI-SYNTHELABO (FR) | 2000-02-22 | — | — | US | disclosed |
| WO-1997010211-A1 | NOVEL HUMAN NK3 RECEPTOR-SELECTIVE ANTAGONIST COMPOUNDS, METHOD FOR OBTAINING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI (FR) | 1997-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006135-A1 | Combination treatment for depression and anxiety | TACR1, NPSR1, HTR3A | TACR2 7/4885TACR1 1/4885TACR3 86/4885 |
| US-20040220223-A1 | Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them | TACR2, BDKRB2, ACKR3 | TACR2 1/4885TACR1 14/4885TACR3 9/4885 |
| US-20020049329-A1 | Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them | TACR2, BDKRB2, ACKR3 | TACR2 1/4885TACR1 14/4885TACR3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.